FY2025 EPS Estimates for Stereotaxis Lowered by Roth Capital

Stereotaxis Inc. (NYSEAMERICAN:STXS) – Equities researchers at Roth Capital cut their FY2025 earnings estimates for Stereotaxis in a report released on Tuesday, November 11th. Roth Capital analyst K. Bauser now expects that the company will earn ($0.26) per share for the year, down from their previous forecast of ($0.24). Roth Capital has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Stereotaxis’ current full-year earnings is ($0.26) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2025 earnings at ($0.06) EPS and Q2 2026 earnings at ($0.06) EPS.

Separately, UBS Group set a $4.00 target price on Stereotaxis in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.00.

Stereotaxis Stock Performance

NYSEAMERICAN:STXS opened at $2.24 on Friday. The business has a 50 day moving average price of $2.94 and a 200-day moving average price of $2.53. Stereotaxis has a fifty-two week low of $1.54 and a fifty-two week high of $3.59. The firm has a market cap of $204.00 million, a PE ratio of -7.72 and a beta of 1.65.

Hedge Funds Weigh In On Stereotaxis

Several institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in shares of Stereotaxis by 106.5% in the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after buying an additional 5,910 shares in the last quarter. Kovack Advisors Inc. raised its position in Stereotaxis by 2.9% in the 3rd quarter. Kovack Advisors Inc. now owns 137,855 shares of the company’s stock worth $429,000 after buying an additional 3,895 shares during the last quarter. Vanguard Group Inc. lifted its stake in Stereotaxis by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after acquiring an additional 138,482 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of Stereotaxis by 3.5% during the 3rd quarter. Essex Investment Management Co. LLC now owns 1,598,114 shares of the company’s stock valued at $4,970,000 after acquiring an additional 53,358 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Stereotaxis in the third quarter worth approximately $413,000. 45.35% of the stock is currently owned by institutional investors.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.